SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-20-016656
Filing Date
2020-07-24
Accepted
2020-07-24 16:07:59
Documents
5
Effectiveness Date
2020-07-24

Document Format Files

Seq Description Document Type Size
1 DEFA14A nc10012491x1_defa14a.htm DEFA14A 16394
2 nc10012491x1_notice001.jpg GRAPHIC 520660
3 nc10012491x1_notice002.jpg GRAPHIC 703698
4 nc10012491x1_notice003.jpg GRAPHIC 340396
5 nc10012491x1_notice004.jpg GRAPHIC 113070
  Complete submission text file 0001140361-20-016656.txt   2328947
Mailing Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB
Business Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB 44 207-400-3351
Myovant Sciences Ltd. (Filer) CIK: 0001679082 (see all company filings)

IRS No.: 000000000 | State of Incorp.: CA | Fiscal Year End: 0331
Type: DEFA14A | Act: 34 | File No.: 001-37929 | Film No.: 201047037
SIC: 2834 Pharmaceutical Preparations